Management of Acute Myeloid Leukemia with Elevated LDH and High Blast Count

Initial Assessment and Stabilization

The presence of 37% blasts in the peripheral blood meets the WHO criteria for acute leukemia and requires immediate intervention 1
Elevated LDH is a marker of high tumor burden and rapid cell turnover, indicating aggressive disease that needs prompt treatment 2
The National Comprehensive Cancer Network recommends assessing for and managing complications of hyperleukocytosis, which may include tumor lysis syndrome, leukostasis, and bleeding risk 3
Tumor lysis syndrome should be managed with hydration, allopurinol or rasburicase, and monitoring of electrolytes 3
Leukostasis should be considered in patients with WBC >100,000/μL and managed with hydroxyurea (up to 50-60 mg/kg/day) to rapidly reduce white blood cell count 3

A complete bone marrow aspiration and biopsy is necessary to confirm diagnosis and obtain material for cytogenetic analysis, molecular studies, and immunophenotyping by flow cytometry 3
The National Comprehensive Cancer Network recommends assessing for CNS involvement if neurologic symptoms are present 3
Molecular studies should include analysis of FLT3, NPM1, IDH1/2, and other mutations 3, 4

The National Comprehensive Cancer Network recommends standard induction chemotherapy with cytarabine and either idarubicin or daunorubicin for patients <60 years of age 3, 4
For patients with FLT3 mutations, midostaurin should be added to the induction chemotherapy regimen 4
For patients ≥60 years who are candidates for intensive therapy, standard-dose cytarabine with idarubicin, daunorubicin, or mitoxantrone is recommended 4
For patients ≥60 years who are not candidates for intensive therapy, hypomethylating agents such as azacitidine or decitabine are preferred 4

Daily complete blood counts should be monitored to assess for cytopenias 3
Frequent electrolyte monitoring is necessary to detect tumor lysis syndrome 3
Bone marrow evaluation should be performed 14-21 days after initiation of induction to assess response 1
Complete remission is defined as <5% blasts in bone marrow with normal maturation of all cell lines and recovery of peripheral blood counts 1, 5

For patients with hyperleukocytosis, leukapheresis should be considered in addition to chemotherapy if symptoms of leukostasis are present 3
Excessive red blood cell transfusions should be avoided in patients with hyperleukocytosis to prevent increased blood viscosity 3

Elevated white blood cell (WBC) counts are observed in a subset of AML patients, particularly those with a high proportion of circulating blasts; the presenting WBC level serves as an important prognostic factor. 6
A considerable proportion of AML patients present with normal or low WBC counts because the diagnostic criterion is ≥20 % blasts in peripheral blood or bone marrow rather than an elevated total leukocyte count. 7, 8
When the WBC exceeds 40,000 /µL at diagnosis, a screening lumbar puncture should be performed during the first remission before consolidation therapy due to the heightened risk of central nervous system involvement. 7

The presence of FLT3‑ITD mutations is specifically linked to elevated WBC counts and higher circulating blast percentages at diagnosis, defining a distinct AML subset with greater disease burden. 9

Rapid cytoreduction with hydroxyurea is essential, and prompt initiation of definitive chemotherapy is the most critical intervention for patients presenting with elevated WBC. 7

The defining feature of AML is the blast percentage, not the absolute WBC count; therefore, clinicians must avoid assuming that all AML cases exhibit leukocytosis. 7, 8
Both a low‑WBC, high‑blast presentation (e.g., pancytopenic AML) and a high‑WBC, lower‑blast presentation (e.g., hyperleukocytic AML) require immediate treatment, although supportive care needs differ markedly. 6